Mechanism of vascular endothelial growth factor expression mediated by cisplatin in human ovarian cancer cells

Biochemical and Biophysical Research Communications

Volumn 358, Issue 1, 2007, Pages 92-98

  Zhong, Xiao Song ^a,b   Liu, Ling Zhi ^a   Skinner, Heath D ^b   Cao, Zongxian ^b   Ding, Min ^c   Jiang, Bing Hua ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b WEST VIRGINIA UNIVERSITY   (United States)

^c NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

Author keywords

Angiogenesis; Cisplatin; HIF 1; Ovarian cancer; VEGF

Indexed keywords

CISPLATIN; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG INHIBITION; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR; CELL LINE, TUMOR; CISPLATIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUCIFERASES; MUTATION; OVARIAN NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 34248169844     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.04.083     Document Type: Article

References (26)

1. Harper P. Current clinical practices for ovarian cancers. Semin. Oncol. 29 (2002) 3-6
2. Gonzalez V.M., Fuertes M.A., Alonso C., and Perez J.M. Is cisplatin-induced cell death always produced by apoptosis?. Mol. Pharmacol. 59 (2001) 657-663
3. McGuire III W.P. Current status of taxane and platinum-based chemotherapy in ovarian cancer. J. Clin. Oncol. 21 (2003) 133-135
4. Selvakumaran M., Pisarcik D.A., Bao R., Yeung A.T., and Hamilton T.C. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res. 63 (2003) 1311-1316
5. Jamieson E.R., and Lippard S.J. Structure, recognition, and processing of cisplatin-DNA adducts. Chem. Rev. 99 (1999) 2467-2498
6. Ferrara N., and Bunting S. Vascular endothelial growth factor, a specific regulator of angiogenesis. Curr. Opin. Nephrol. Hypertens. 5 (1996) 35-44
7. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1 (1995) 27-31
8. Neufeld G., Cohen T., Gengrinovitch S., and Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13 (1999) 9-22
9. Carmeliet P., Moons L., Dewerchin M., Mackman N., Luther T., Breier G., Ploplis V., Muller M., Nagy A., Plow E., Gerard R., Edgington T., Risau W., and Collen D. Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system. Ann. N. Y. Acad. Sci. 811 (1997) 191-206
10. Ferrara N., Carver-Moore K., Chen H., Dowd M., Lu L., O'Shea K.S., Powell-Braxton L., Hillan K.J., and Moore M.W. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380 (1996) 439-442
11. Olson T.A., Mohanraj D., Carson L.F., and Ramakrishnan S. Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res. 54 (1994) 276-280
12. Hazelton D.A., and Hamilton T.C. Vascular endothelial growth factor in ovarian cancer. Curr. Oncol. Rep. 1 (1999) 59-63
13. Senger D.R., Van de W.L., Brown L.F., Nagy J.A., Yeo K.T., Yeo T.K., Berse B., Jackman R.W., Dvorak A.M., and Dvorak H.F. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev. 12 (1993) 303-324
14. Holash J., Davis S., Papadopoulos N., Croll S.D., Ho L., Russell M., Boland P., Leidich R., Hylton D., Burova E., Ioffe E., Huang T., Radziejewski C., Bailey K., Fandl J.P., Daly T., Wiegand S.J., Yancopoulos G.D., and Rudge J.S. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. USA 99 (2002) 11393-11398
15. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., and Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362 (1993) 841-844
16. Prewett M., Huber J., Li Y., Santiago A., O'Connor W., King K., Overholser J., Hooper A., Pytowski B., Witte L., and Bohlen P.D.J. Hicklin, antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 59 (1999) 5209-5218
17. Jiang B.H., Agani F., Passaniti A., and Semenza G.L. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res. 57 (1997) 5328-5335
18. Rak J., Filmus J., Finkenzeller G., Grugel S., Marme D., and Kerbel R.S. Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev. 14 (1995) 263-277
19. Semenza G.L. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit. Rev. Biochem. Mol. Biol. 35 (2000) 71-103
20. Jiang B.H., Rue E., Wang G.L., Roe R., and Semenza G.L. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J. Biol. Chem. 271 (1996) 17771-17778
21. 2 tension. Proc. Natl. Acad. Sci. USA 92 (1995) 5510-5514
22. 2 tension. Am. J. Physiol. 271 (1996) C1172-C1180
23. El Awad B., Kreft B., Wolber E.M., Hellwig-Burgel T., Metzen E., Fandrey J., and Jelkmann W. Hypoxia and interleukin-1beta stimulate vascular endothelial growth factor production in human proximal tubular cells. Kidney Int. 58 (2000) 43-50
24. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D., and Semenza G.L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell Biol. 16 (1996) 4604-4613
25. Kimura H., Weisz A., Ogura T., Hitomi Y., Kurashima Y., Hashimoto K., D'Acquisto F., Makuuchi M., and Esumi H. Identification of hypoxia-inducible factor 1 ancillary sequence and its function in vascular endothelial growth factor gene induction by hypoxia and nitric oxide. J. Biol. Chem. 276 (2001) 2292-2298
26. Richard D.E., Berra E., and Pouyssegur J. Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells. J. Biol. Chem. 275 (2000) 26765-26771